Clinical Trials Browser

Congenital Abnormalities, Blast Crisis, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00625729 2017-12-28

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Phase 1/2 Terminated

6 enrolled 10 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT00871689 2017-12-28

Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML

Phase 2 Terminated

2 enrolled 13 charts

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Leukemia, Myeloid, Acute

NCT01464359 2017-12-28

T-Cell Depleted Double UCB for Refractory AML

Phase 2 Terminated

3 enrolled 9 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02259348 2017-05-30

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

Phase 2 Terminated

12 enrolled 12 charts

LymphoidMyeloidOther hematologic neoplasmSarcoma

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT01517347 2016-10-24

Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation

Phase NA Terminated

90 enrolled

Other hematologic neoplasm

Leukemia, Recurrence

NCT00941928 2014-05-22

Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)

Phase 2 Terminated

2 enrolled 3 charts

LymphoidOther hematologic neoplasm

Leukemia, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

NK4AML

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

FT516 in Subjects With Advanced Hematologic Malignancies

Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML

T-Cell Depleted Double UCB for Refractory AML

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation

Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)